SCHEMBL17048614

SCHEMBL17048614

CC(C)(C)OC(=O)N=Cc1ccc(C#N)cc1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.45
▸ ALDH1A1 P00352 3/20 0.45
▸ LMNA P02545 2/20 0.45
▸ GAA P10253 2/20 0.45
▸ KMT2A Q03164 4/20 0.43
▸ MEN1 O00255 3/20 0.43
▸ MIF P14174 1/20 0.41
▸ SMN1; SMN2 Q16637 3/20 0.40
▸ RAB9A P51151 3/20 0.40
▸ NPC1 O15118 2/20 0.40
▸ GPR119 Q8TDV5 2/20 0.40
▸ RECQL P46063 1/20 0.40
▸ HDAC2 Q92769 2/20 0.40
▸ MAPT P10636 4/20 0.40
▸ HTT P42858 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ FBP1 P09467 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38
▸ KIF11 P52732 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18665796 1.00 KDM4E (0.45) KDM4EALDH1A1LMNAGAAKMT2A
SCHEMBL17048612 1.00 KDM4E (0.45) KDM4EALDH1A1LMNAGAAKMT2A
SCHEMBL29219514 0.81 MIF (0.45) KDM4EALDH1A1LMNAGAAKMT2A
SCHEMBL29219460 0.80 CA2 (0.48) KDM4ELMNAGAAKMT2AMEN1
SCHEMBL20521947 0.80 MIF (0.44) KDM4EALDH1A1KMT2AMEN1MIF
SCHEMBL29219498 0.80 NPC1 (0.61) KDM4EALDH1A1LMNAKMT2AMEN1
SCHEMBL17302200 0.80 NPC1 (0.61) KDM4EALDH1A1LMNAKMT2AMEN1
SCHEMBL29219426 0.80 MIF (0.44) KDM4ELMNAMIFSMN1; SMN2RAB9A
SCHEMBL29846226 0.80 MIF (0.44) KDM4ELMNAMIFSMN1; SMN2RAB9A
SCHEMBL1699068 0.80 MIF (0.44) KDM4EALDH1A1KMT2AMEN1MIF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117946023-A Preparation method of trans-4, 5-disubstituted oxazolidone compound 南京工业大学 2024-04-30 — — CN disclosed
EP-3110810-B1 PYRAZOLE AMIDE DERIVATIVE TEIJIN PHARMA LTD (JP) 2018-05-02 — — EP disclosed
EP-3110810-A1 PYRAZOLE AMIDE DERIVATIVE Teijin Pharma Limited (JP) 2017-01-04 — — EP disclosed
US-9365522-B2 Pyrazole amide derivative AMGEN INC. (US) 2016-06-14 — — US disclosed
US-20150266824-A1 Pyrazole Amide Derivative TEIJIN LIMITED (JP) 2015-09-24 — — US disclosed
WO-2015129926-A1 PYRAZOLE AMIDE DERIVATIVE TEIJIN PHARMA LIMITED (JP) 2015-09-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150266824-A1 Pyrazole Amide Derivative RORC, RORB, RORA KDM4E 986/4885ALDH1A1 923/4885LMNA 4719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback